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Introduction
The physiological functions of ERK8 (extracellular signal-
regulated kinase 8) are unknown. It is most closely related to 
ERK1/2 and ERK5 by virtue of a Thr-Glu-Tyr (T-E-Y) activation 
motif that must be phosphorylated in order for the kinase to be ac-
tive (Abe et al., 2002). Unlike ERK1/2, ERK8 and ERK5 contain 
C-terminal extensions. ERK8 appears to be a rapidly evolving ki-
nase (Coulombe and Meloche, 2007). The C-terminal tail of ERK8 
is 51% conserved between primates and other mammals, in 
contrast to ERK5 in which the tail is 96% conserved. Given the 
paucity of information on ERK8, we investigated its function.
Proliferating cell nuclear antigen (PCNA) is a key player 
in a variety of DNA metabolic pathways in which it coordinates 
and regulates the functions of numerous proteins that perform 
enzymatic reactions on DNA (Moldovan et al., 2007). PCNA 
exists as a homotrimer that encircles DNA and provides a plat-
form for its interacting partners. In addition to facilitating com-
plex assembly, PCNA is able to stimulate or inhibit the activity 
of some of its binding partners (Gomes and Burgers, 2000; 
Azam et al., 2001). Intensive efforts have revealed the docking 
domains that facilitate interaction with PCNA (Moldovan et al., 
2007; Gilljam et al., 2009; Havens and Walter, 2009). It is hy-
pothesized that PCNA controls the myriad processes involved 
in genomic stability by direct physical association with its nu-
merous binding partners (Moldovan et al., 2007). A decrease in 
PCNA protein levels prevents the formation of complexes nec-
essary for DNA metabolism and results in catastrophic conse-
quences (Jaskulski et al., 1988; Henderson et al., 1994). Thus, it 
is essential for cell survival to maintain PCNA protein levels at 
a critical threshold. PCNA is covalently modified by ubiquitin 
(Andersen et al., 2008; Das-Bradoo et al., 2010) and SUMO 
(small ubiquitin-like modifier; Hoege et al., 2002), but these 
modifications are thought to control the association with bind-
ing partners and not in the regulation of degradation. Thus, little 
is known about the regulation of PCNA protein turnover.
We have discovered that ERK8 controls PCNA levels in 
normal cycling cells by preventing its destruction via human 
P
roliferating cell nuclear antigen (PCNA) acts as a 
scaffold, coordinator, and stimulator of numerous 
processes required for faithful transmission of ge-
netic information. Maintaining PCNA levels above a criti-
cal threshold is essential, but little is known about PCNA 
protein turnover. We now show that ERK8 (extracellular 
signal-regulated kinase 8) is required for PCNA protein 
stability.  ERK8  contains  a  conserved  PCNA-interacting 
protein (PIP) box. Chromatin-bound ERK8 (ERK8
CHROMATIN) 
interacts via this motif with PCNA
CHROMATIN, which acts 
as a platform for numerous proteins involved in DNA   
metabolism. Silencing ERK8 decreases PCNA levels and in-
creases DNA damage. Ectopic expression of PCNA blocks 
DNA damage induced by ERK8 loss. ERK8 prevents HDM2-
mediated PCNA destruction by inhibiting the association 
of PCNA with HDM2. This regulation is physiologically 
relevant as ERK8 activity is inhibited in transformed mam-
mary cells. Our results reveal an unanticipated mecha-
nism to control PCNA levels in normal cycling mammary 
epithelial cells and implicate ERK8 in the regulation of 
genomic stability.
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Figure 1.  ERK8 regulates proliferation of MCF-10A cells. (A) Analysis of endogenous ERK8 knockdown in MCF-10A cells transduced with shRNA to 
luciferase (Luc) or one of two different ERK8 targeting sequences for 5 d. The detergent-insoluble fraction (I) of the transduced lysates was normalized for 
Ran expression and immunoblotted for ERK8. (B) Scatter plot showing the rate of proliferation of transduced MCF-10A cells. Analysis was started 2 d after 
transduction. Mean is shown (n = 5, quadruplicates), and error bars indicate SEM. (C) A representative flow cytometric analysis of cell cycle progression 
in MCF-10A cells transduced as in A. Transduced cells were identified by GFP fluorescence, and DNA was stained with DRAQ5. The times indicated 
are sampling times after the cells were arrested by serum and growth factor depletion, followed by release into the cell cycle by the addition of complete   
media. The table summarizes the results (mean ± range [n = 2]) generated by ModFit LT (Verity Software House). (D) Analysis of whole cell extracts (WCE) 
of MCF-10A cells transduced as in A. The lysates were normalized for Ran expression and immunoblotted for regulators of the cell cycle and DNA damage. 577 ERK8 and genomic integrity • Groehler and Lannigan
The decrease in PCNA was not correlated with a particular stage 
in the cell cycle, as total PCNA levels did not change during the 
cell cycle (Fig. 1 F). In agreement with the literature (Naryzhny 
and Lee, 2001), the subcellular distribution of PCNA changed 
during the cell cycle such that during S phase, PCNA preferen-
tially partitioned into a detergent-insoluble fraction (Fig. 1 F and 
Fig. S1 B). Loss of ERK8 appeared to specifically reduce PCNA 
levels as we did not observe a decrease in the level of Rad9, a 
component  of  the  heterotrimeric  complex  9-1-1,  which,  like 
PCNA, encircles DNA and is involved in DNA damage repair 
(Fig. 1 D; St Onge et al., 1999). Moreover, the level of RFC-1 
(replication factor C-1), a subunit of the clamp loader that loads 
PCNA onto DNA (Waga and Stillman, 1998), was not changed 
(Fig. 1 D). We conclude that silencing ERK8 results in a specific 
decrease in PCNA protein levels.
To determine whether the reduction of PCNA levels caused 
by  ERK8  depletion  is  physiologically  significant,  we  asked 
whether silencing ERK8 increases DNA damage, as PCNA is 
essential for genomic integrity (Umar et al., 1996; Gary et al., 
1997; Hoege et al., 2002; Unk et al., 2002; Zhang et al., 2003; 
Xia et al., 2005). Staining with an antibody to phospho-Ser139 
in H2AX (-H2AX), a marker of DNA double-stranded breaks 
(Rogakou et al., 1999; Sedelnikova et al., 2003), resulted in a 
twofold increase in -H2AX staining in ERK8-depleted cells 
compared with the control, even in the absence of extrinsic geno-
toxic stress (Fig. 2 A and Fig. S2 A). PCNA acts to repair DNA 
in response to irradiation with UVC radiation (Essers et al., 2005). 
Therefore, we determined whether loss of ERK8 would further 
increase DNA damage in response to UVC irradiation. In re-
sponse to UVC, both ATR (ataxia telangiectasia and Rad3 re-
lated) and Chk2 were activated, although loss of ERK8 reduced 
the level of Chk2 activation (Fig. S2 B). However, the intensity 
of -H2AX staining increased in parallel in the silenced and con-
trol cells up to 2 h after UVC treatment (Fig. 2 A and Fig. S2 A). 
Strikingly, however, although at 4 h the amount of -H2AX 
staining decreased in the control cells, it remained elevated when 
ERK8 was absent. We confirmed that the increased -H2AX 
staining was a result of DNA breaks using the comet assay.   
Silencing ERK8 in the absence of extrinsic genotoxic stress re-
sulted in an approximately threefold increase in comet tail length 
compared with the control (Fig. 2, B and F). Moreover, in re-
sponse to UVC treatment, the knockdown of ERK8 resulted in 
longer tail lengths compared with the control (Fig. 2, B and F). 
We conclude that ERK8 is not required for the initial response to 
DNA damage but is required for genomic stability most likely 
through its ability to maintain PCNA protein levels.
If the effects of ERK8 are mainly caused by a decrease in 
PCNA levels, depleting PCNA should phenocopy the knock-
down of ERK8. Consistent with our observations with ERK8, 
we  observed  that  silencing  PCNA  inhibited  proliferation  of 
MCF-10A cells (Fig. 2 C). Moreover, in the absence of extrinsic 
genotoxic stress, loss of PCNA resulted in an increased level of 
homologue of murine double minute (HDM2). Loss of ERK8 
resulted in genomic instability by decreasing PCNA levels be-
yond a tolerated limit. ERK8 was active in a mammary epithe-
lial cell line and in primary mammary cells but was inactivated 
in breast cancer cell lines. These data argue that ERK8 control 
of PCNA levels is physiologically relevant, as ERK8 activity is 
inhibited in transformed cells.
Results
ERK8 regulates the cell cycle by 
maintaining PCNA levels
We investigated potential physiological functions for ERK8 by   
silencing its expression in the human breast epithelial line,   
MCF-10A. Successful silencing of endogenous ERK8, which was 
localized predominantly to a detergent-insoluble fraction, was ob-
served with two different short hairpin RNAs (shRNAs; Fig. 1 A). 
Proliferation was measured starting at 2 d after transduction.   
Based on the doubling time of the control cells (31.9 ± 0.08 h), the 
transduced cells doubled approximately once before measuring 
the proliferation rate. Knockdown of ERK8 decreased prolifera-
tion approximately twofold, which was prevented by expression   
of a mutant ERK8 resistant to silencing (rERK8; Fig. 1 B and   
Fig. S1 A). In agreement with the silencing experiments, ectopic 
expression of wild-type ERK8 enhanced proliferation (Fig. 1 B).   
The most effective knockdown of ERK8 occurred 4–5 d after trans-
duction, and therefore, the majority of experiments were performed 
using cells transduced in this time frame. To investigate the mecha-
nism by which ERK8 controls the cell cycle, we performed flow 
cytometry using cells synchronized by serum and growth factor 
depletion, which resulted in 70% of the control cells in G1. The 
addition of serum and growth factors to the control cells resulted in 
a threefold increase in the number of cells in S phase after 24 h   
(Fig. 1 C). In contrast to these results, no change in the cell cycle dis-
tribution after release from starvation was observed when ERK8 
was silenced (Fig. 1 C). Collectively, these results demonstrate that 
ERK8 is a limiting factor in regulating the proliferation rate of 
MCF-10A cells and controls entry into S phase.
While analyzing cell cycle markers, we noticed that loss of 
ERK8 resulted in increases in cyclin D1, cyclin E, and p27 and a 
decrease in cyclin A levels compared with the control (Fig. 1 D). 
Furthermore, retinoblastoma (Rb) appeared as a doublet in the 
immunoblot analysis, and loss of ERK8 reduced the level of the 
higher molecular weight form (Fig. 1 D). These observations are 
consistent with a reduction in the phosphorylated form of Rb. 
Collectively, these changes provide further evidence that loss of 
ERK8 results in a cell cycle block in the G1/S phase and are in 
agreement with our flow cytometry results. But, unexpectedly, 
loss of ERK8 resulted in a decrease in the total level of PCNA 
(Fig. 1, D and E; and see Fig. 4 B). Silencing ERK8 did not re-
sult in higher molecular weight forms of PCNA that could ac-
count for the decrease in the unmodified form (Figs. 1 D and 2 E). 
(E) Quantitation of the relative amount of PCNA in comparison to Ran and normalized to the control, which was transduced with luciferase shRNA. Mean 
is shown (n = 6), and error bars indicate SEM. (F) Cell cycle analysis of PCNA in whole cell extracts and detergent-insoluble (I) and -soluble (S) fractions. 
MCF-10A cells were arrested and released into the cell cycle as in C. LV, lentivirus.
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Figure 2.  ERK8 regulates DNA repair by a PCNA-dependent mechanism. (A) Analysis of DNA damage by -H2AX immunofluorescence in ERK8 knock-
down cells. MCF-10A cells transduced for 5 d were treated with or without () 20 J/m
2 UVC. The times indicated refer to the length of time after irradia-
tion. At the indicated time, the cells were treated with detergent, fixed, and immunostained with an anti–-H2AX antibody and an anti–mouse fluorescent 
secondary antibody. Nuclei were stained with DRAQ5. The intensity of -H2AX staining was determined and normalized to the levels obtained in the 
control cells, which were transduced with luciferase (Luc) shRNA and not irradiated. Mean is shown (n = 2, duplicates, ≥35 cells/condition), and error 
bars indicate SEM. (B) Analysis of DNA damage by comet assay of cells transduced as in A, without irradiation or 2 h after UVC treatment. DNA was 
visualized by staining with Sybr green (Trevigen, Inc.). Bar, 50 µm. (C) Rate of proliferation of MCF-10A cells transfected with control or PCNA-specific 
siRNA. The rate of proliferation was determined over 48 h, starting at 2 d after transfection. Mean is shown (n = 4, sextuplicate), and error bars indicate 
SEM. The right panel shows the extent of PCNA knockdown 4 d after transfection in lysates normalized for Ran. (D) Analysis of DNA damage by -H2AX 
immunofluorescence in PCNA knockdown cells. Cells transfected as in C were treated as in A, and the intensity of -H2AX staining was determined and 579 ERK8 and genomic integrity • Groehler and Lannigan
wash extraction, which indicates that there is a pool of ERK8 and 
PCNA that has a high affinity for chromatin (Fig. S3 A). Based 
on these observations, we used a modified chromatin immuno-
precipitation assay and found that, in the presence of DNase I, 
chromatin-bound HA-tagged ERK8 (HA-ERK8
CHROMATIN) asso-
ciated with PCNA
CHROMATIN (Fig. 3 A). Furthermore, endogenous 
PCNA
CHROMATIN  associated  with  endogenous  ERK8
CHROMATIN 
(Fig. 3 B). A fraction of PCNA and ERK8 was not associated 
with chromatin, and HA-ERK8 obtained from this soluble frac-
tion (HA-ERK8
FREE) and PCNA
FREE did not interact (Fig. 3 A). 
Most of the interacting partners for PCNA interact through a 
conserved motif called the PIP box (Warbrick, 1998; Moldovan 
et al., 2007). We identified a putative PIP box in ERK8, spe-
cifically the sequence from 297 to 308 (QALQHPYVQRFH; 
ERK8 (PIP)), where bold indicates a match with the conserved 
motif (Fig. S3 B). The spacing between the Q and the V is usually 
two residues; however, DNA polymerase  has a three-residue 
spacing, like ERK8 (Kedar et al., 2002). A GST fusion protein 
containing the putative ERK8 PIP box (GST–ERK8 (PIP)) inter-
acted with PCNA
FREE (Fig. 3 C), but a mutant PIP box, in which the 
residue corresponding to Gln300 was mutated to Ala (GST–ERK8 
(PIPm)) did not interact. Further confirmation that ERK8 con-
tains a PIP box was shown by mutation of Gln300 to Ala within 
the context of the full-length kinase (ERK8(Q300A)). This mu-
tant did not associate with PCNA
CHROMATIN even though it was 
able to bind chromatin (Fig. 3 D and Fig. S3 C). Collectively, we 
conclude that ERK8
CHROMATIN associates with PCNA
CHROMATIN 
via the PIP box.
-H2AX staining compared with the control (Fig. 2 D and 
Fig. S2 C). Furthermore, at 4 h, although DNA repair started to 
occur in the control cells, the level of -H2AX staining remained 
elevated in the absence of PCNA. These results are consistent 
with our hypothesis that ERK8 controls genomic integrity via 
regulation of PCNA protein levels. To further test our hypothe-
sis that ERK8 acts primarily through PCNA, we asked whether 
the ectopic expression of PCNA would reverse the decrease in 
proliferation caused by reduced ERK8 levels. MCF-10A cells 
were transduced with mRFP-tagged PCNA (mRFP-PCNA)   
or the mRFP control and then transduced a second time with 
ERK8-specific or control shRNA. In agreement with our earlier 
results, silencing ERK8 reduced proliferation; however, impor-
tantly, the overexpression of PCNA after silencing ERK8 pre-
vented the decrease in proliferation (Fig. 2 E). Additionally, the 
forced expression of PCNA alleviated the DNA damage caused 
by loss of ERK8 (Fig. 2 F and Fig. S2 D). Collectively, these 
data support the surprising conclusion that ERK8 is essential   
to maintain PCNA expression at a level that prevents DNA repli-
cation stress in normal cycling cells (Halazonetis et al., 2008).
ERK8 interacts and controls PCNA 
turnover via a PCNA-interacting protein 
(PIP) box
To  determine  how  ERK8  controls  PCNA  levels,  we  asked 
whether ERK8 and PCNA physically associate. A fraction of 
wild-type Venus-tagged ERK8 (Venus-ERK8) and endogenous 
PCNA associated with chromatin after a detergent and high salt 
normalized to the levels obtained in the control cells, which were transfected with control siRNA and not irradiated. Mean is shown (n = 2, duplicates,   
≥40 cells/condition), and error bars indicate SEM. (E) Rescue of proliferation by ectopic expression of PCNA in ERK8 knockdown cells. MCF-10A cells were 
transduced with mRFP or mRFP-PCNA and then transduced a second time with control or ERK8-specific shRNA. The rate of proliferation was determined 
over 48 h, starting at 4 d after transduction. Mean is shown (n = 4, quadruplicate), and error bars indicate SEM. The right panel shows the level of mRFP-
PCNA (62 kD) in comparison with endogenous PCNA (34 kD). (F) Comet assay of MCF-10A cells transduced as in E. Transduced cells were treated   
as in B, and tail length was measured. Mean is shown (n = 2, duplicates), and error bars indicate SEM. The right panel shows the level of mRFP-PCNA 
(62 kD) in comparison with endogenous PCNA (34 kD). LV, lentivirus; WCE, whole cell extract.
 
Figure 3.  ERK8 interacts with PCNA via a   
PIP box. (A and B) Chromatin was immuno-
precipitated with antibodies against ectopically 
expressed  HA-tagged  ERK8  (A)  or  endog-
enous PCNA (B), treated with DNase I, and 
analyzed  by  immunoblotting.  A  fraction  of 
the input is shown for comparison to the level 
of associated PCNA or ERK8. (C) GST–ERK8   
(PIP) fusion proteins were immunoprecipitated 
with antibodies to PCNA. The soluble frac-
tion of MCF-10A lysates was incubated with   
GST-PIP  box  fusions  containing  the  wild- 
type (QALQHPYVQRFH) or mutant ERK8 PIP   
(QALAHPYVQRFH) box. PCNA was immuno-
precipitated  and  electrophoresized,  and 
associating  proteins  were  analyzed  by   
immunoblotting. A fraction of the input is shown 
for  comparison  to  the  level  of  associated   
GST–ERK8 (PIP). (D) Chromatin was immuno-
precipitated  with  antibodies  (Ab)  against 
ectopically expressed HA-tagged wild type or 
ERK8(Q300A) mutant, treated with DNase I, 
and analyzed by immunoblotting. A fraction of 
the input is shown for comparison to the level 
of associated PCNA. I, insoluble fraction; IP, 
immunoprecipitation; S, soluble fraction.JCB • VOLUME 190 • NUMBER 4 • 2010   580
of PCNA
CHROMATIN by 60% compared with the control. Consis-
tent with these observations, total PCNA in ERK8-depleted cells 
was reduced approximately twofold relative to the control after 
a 12-h treatment with the protein synthesis inhibitor cyclohexi-
mide (Fig. S3 E). Thus, loss of ERK8 enhances PCNA
CHROMATIN 
turnover. Mutation of Tyr211 has been reported to destabilize 
PCNA (Wang et al., 2006). However, we did not detect any Tyr 
phosphorylation  of  PCNA  (Fig.  S3  F). These  results  are  in 
agreement with orthophosphate labeling analysis of PCNA, 
which also did not detect phosphorylation of PCNA (Naryzhny 
and Lee, 2004). We propose that the increase in PCNA
CHROMATIN 
turnover caused by the loss of ERK8 indirectly decreases   
PCNA
FREE levels because of continued recruitment of PCNA
FREE 
to the chromatin in an effort to maintain critical cellular func-
tions (Fig. 5 A). This hypothesis is consistent with the literature 
in which increasing the extent of DNA damage leads to deple-
tion of PCNA
FREE (Mortusewicz and Leonhardt, 2007).
We next asked whether the interaction of ERK8 with PCNA 
is necessary for stabilization of PCNA. MCF-10A cells were 
transduced with Venus-rERK8, Venus–rERK8 PIP mutant (Venus-
rERK8(Q300A)), or the Venus control and then transduced a 
second time with ERK8-specific or control shRNA. Expression 
of resistant ERK8 prevented the decrease in PCNA levels caused 
by silencing of endogenous ERK8 (Fig. 4 B). However, impor-
tantly, the ERK8 PIP mutant was unable to rescue PCNA levels 
even though the level of rERK8(Q300A) and its ability to asso-
ciate with the chromatin was similar to that of the wild type 
(Fig. 4 B and Fig. S3 C). Furthermore, the mutant was as active 
as the wild type, as shown by the anti-pERK8 antibody (Fig. 4 B). 
This antibody recognizes the dual phosphorylation of the T-E-Y 
motif, which must be phosphorylated for members of the ERK1/2 
family to be active (Her et al., 1993). Therefore, the pERK8 levels 
reflect the amount of active kinase. Surprisingly, expression   
of the ERK8 PIP mutant caused an at least twofold decrease in 
PCNA levels even in the presence of endogenous ERK8. These 
results indicate that ERK8(Q300A) acts as a dominant-negative, 
most likely by competing with endogenous ERK8 for binding 
to chromatin, thereby blocking association of the endogenous 
ERK8 with PCNA, which permits PCNA destruction. Collec-
tively, our data support a model in which ERK8
CHROMATIN stabi-
lizes  PCNA  by  inhibiting  access  to  PCNA
CHROMATIN  of  a 
destruction factor. This is the first report of a PCNA-binding 
partner that regulates PCNA stability during normal cell cycling 
(Izumi et al., 2001; Wang et al., 2006; Yu et al., 2009).
ERK8 inhibits the interaction of PCNA 
with HDM2
PCNA is able to act as a platform to mediate the degradation of 
some of its binding partners via a specialized PIP box (Havens 
and Walter, 2009). However, information on how PCNA turn-
over is regulated in normal cycling cells is lacking. In response 
to DNA damage to UV, PCNA destruction has been shown to 
occur via the 26S proteasome pathway (Yu et al., 2009). There-
fore, we reasoned that an E3 ligase, which is able to compete for 
ERK8 binding to PCNA, may also control PCNA turnover in nor-
mal cycling cells. HDM2 is the only currently known E3 ligase 
that interacts with PCNA through a PIP box (Banks et al., 2006), 
We next asked whether ERK8 controls PCNA protein   
stability by pulse-chase labeling with [
35S]Met. The degrada-
tion rate of PCNA
FREE, which does not interact with ERK8,   
was similar in the presence and absence of ERK8 (Fig. 4 A and 
Fig. S3 D). However, silencing ERK8 increased the destruction 
Figure 4.  The association of ERK8 with PCNA inhibits PCNA protein turn-
over. (A) Time course of PCNA degradation by [
35S]Met pulse-chase label-
ing. MCF-10A cells transduced for 5 d were depleted of intracellular Met, 
labeled with [
35S]Met for 4 h, washed, and incubated in excess cold Met 
for 0 or 12 h. Lysates were separated into insoluble (I) and soluble (S) 
fractions, and each fraction was immunoprecipitated with an anti-PCNA 
antibody. The amount of [
35S]Met labeling was divided by the relative level 
of immunoprecipitated PCNA and then normalized to the control, which 
was transduced with luciferase (Luc) shRNA and analyzed at 0 h after the 
addition of excess, cold Met. Mean is shown (n = 3, duplicates), and error 
bars indicate SEM. (B) Rescue of PCNA levels by ectopic expression of re-
sistant ERK8 (rERK8). MCF-10A cells were transduced with resistant ERK8 
constructs or Venus control, followed by a second transduction with control 
or ERK8-specific shRNA. Lysates were taken 5 d after transduction, normal-
ized for Ran expression, and immunoblotted for PCNA. The bottom panel 
shows the expression levels and activation of the Venus-ERK8(Q300A) in 
comparison with wild type. IP, immunoprecipitation; LV, lentivirus; WCE, 
whole cell extract.581 ERK8 and genomic integrity • Groehler and Lannigan
silenced ERK8 and then transfected with control or HDM2 
siRNA. Additionally, we transfected with a plasmid encoding a 
six-His tag fused to ubiquitin (His6-Ub). Loss of HDM2 de-
creased the levels of ubiquitinated PCNA (Fig. 5 A). Knock-
down of ERK8 did not alter the levels of HDM2 (Fig. 5 B). 
However, silencing ERK8 increased the association of PCNA 
with HDM2 (Fig. 5 B). We conclude that ERK8 inhibits PCNA 
degradation by inhibiting its association with HDM2, which fa-
cilitates PCNA degradation via the 26S proteasome pathway.
ERK8 is activated by chromatin binding
It has been reported that ERK8 activity is increased in response 
to various DNA-damaging agents (Klevernic et al., 2009).   
Using identical conditions as reported by Klevernic et al. (2006, 
2009), we observed changes in ERK8 activity only in response 
to 1 mM H2O2 (Fig. S5 A). We did not observe changes in ERK8 
protein levels with any of the DNA-damaging reagents tested. 
Activation of ERK1/2 was dose dependent on H2O2, but ERK8 
activation was observed only at 1 mM H2O2 (Fig. S5 B). This 
concentration of H2O2 was extremely toxic and resulted in cell 
death within 3 h, and therefore, it is difficult to determine the 
physiological relevance of this observation. We conclude that in 
MCF-10A cells, DNA-damaging agents do not enhance activa-
tion of ERK8, and basal levels of ERK8 activation are sufficient 
to stabilize PCNA levels.
Active ERK8, as shown by pERK8, is mainly present in 
the insoluble fraction (Fig. S5 C). These results are consistent 
and therefore, it could possibly compete with ERK8 for bind-
ing to PCNA. However, it is not known whether HDM2 targets 
PCNA for destruction. We observed that silencing HDM2 re-
sulted in an increase in PCNA levels (Fig. 5 A). These results 
suggest that HDM2 regulates PCNA turnover in normal cycling 
cells. However, as HDM2 regulates p53 levels, knockdown of 
HDM2 will result in an increase in p53 levels and disruption of 
the cell cycle (Martin et al., 1995). To investigate whether ele-
vated p53 levels could increase PCNA levels, we used the in-
hibitor nutlin-3 (Vassilev et al., 2004). As expected by disrupting 
the association of HDM2 and p53, the levels of both proteins 
increased substantially (Fig. S4). We also observed that nutlin-3 
altered the electrophoretic mobility of Rb to generate a single 
immunoreactive band (Fig. S4), which is consistent with the 
unphosphorylated form of Rb. Unphosphorylated Rb binds and 
inhibits E2F (Stevens and La Thangue, 2003), which can result 
in decreased expression of some E2F-regulated genes such as 
PCNA (Black et al., 2005). However, treatment with nutlin-3 
did not alter the levels of PCNA. These results indicate that the 
increase in PCNA levels in response to the loss of HDM2 is   
independent of p53 and the phosphorylation status of Rb.   
To investigate whether HDM2 facilitates PCNA turnover in the   
absence of ERK8, we silenced both HDM2 and ERK8. Strik-
ingly, the decrease in PCNA levels caused by the loss of ERK8 
was reversed by also silencing HDM2 expression (Fig. 5 A). 
From this data, we would predict that the loss of HDM2 would 
prevent ubiquitination of PCNA. To test this hypothesis, we 
Figure 5.  ERK8 regulates the association of 
PCNA  with  HDM2.  (A)  Silencing  HDM2  en-
hances PCNA levels in the absence or pres-
ence of ERK8. MCF-10A cells were transduced 
with control (con) or ERK8-specific shRNA, fol-
lowed by transfection with control or HDM2 
siRNA. Lysates were taken 5 d after transduc-
tion and divided into insoluble (I) and soluble 
(S) fractions, normalized for Ran levels, and 
immunoblotted for PCNA. The top right panel 
shows the extent of HDM2 knockdown in ly-
sates normalized for Ran levels. Quantitation 
of the relative amount of PCNA in compari-
son to Ran and normalized to the appropriate 
control,  which  was  transduced  with  lucifer-
ase (Luc) shRNA and transfected with control 
siRNA. Mean is shown (n = 3), and error bars 
indicate  SEM.  Silencing  HDM2  decreased 
levels of ubiquitinated PCNA. MCF-10A cells 
were transduced with ERK8-specific shRNA fol-
lowed by transfection with a plasmid encoding 
His6-Ub and control or HDM2 siRNA. PCNA 
was  immunoprecipitated  5  d  after  trans-
duction, and the normalized PCNA immuno-
precipitates were analyzed for ubiquitination. 
The IgG band is from the immunoprecipitating 
antibody. (B) Loss of ERK8 increases the asso-
ciation of HDM2 with PCNA. MCF-10A cells 
were transduced with control or ERK8-specific 
shRNA  for  5  d.  PCNA  was  immunoprecipi-
tated, and the normalized PCNA immunopre-
cipitates were analyzed for HDM2. The right 
panel shows the level of HDM2 expression in 
lysates normalized for Ran. IP, immunoprecipi-
tation; LV, lentivirus; WCE, whole cell extract.JCB • VOLUME 190 • NUMBER 4 • 2010   582
showed defective chromatin association (Fig. 6 D and Fig. S5 E). 
We conclude that the PXXXP motif acts as an autoinhibitory 
regulator of kinase activity. We propose that the mutation mim-
ics the conformational change that occurs upon association of 
ERK8 with chromatin, which relieves autoinhibition. We con-
clude that binding to chromatin activates ERK8, independently 
of PCNA binding.
ERK8 stabilizes PCNA in primary 
mammary epithelial cells
ERK8 was detected in the detergent-insoluble fraction of pri-
mary human mammary epithelial (HME) cells at levels similar 
to MCF-10A cells (Fig. 7 A). Importantly, silencing ERK8 in 
HME cells decreased PCNA levels (Fig. 7 B), and this reduction 
in PCNA was accompanied by a substantial increase in the fre-
quency of DNA breaks for both untreated and UVC-irradiated 
HME cells (Fig. 7 B). The fold increase in comet length in HME 
cells ranged from 2–10-fold in the absence of UVC, and this 
range probably reflects the genetic differences between patient 
samples. Thus, the regulation of PCNA by ERK8 is not an arti-
fact of the MCF-10A immortalized cell line but occurs also in 
primary mammary cells.
ERK8 is inactive in transformed  
breast lines
Our results predict that loss of ERK8 will lead to genomic instabil-
ity. To test this prediction, we silenced ERK8 in MCF-10A cells and 
maintained the cells in culture for 2 wk. Analysis of the nuclei of 
with the immunofluorescence data that show that a kinase-dead 
mutant of ERK8 (ERK8(K42A)) does not associate with the 
chromatin (Fig. S3 A). This mutant has the essential Lys residue 
that is necessary for interaction with ATP mutated to Ala (Abe 
et al., 2002). It is possible that the interaction of PCNA activates 
ERK8, like Chk1 (Scorah et al., 2008). However, pERK8 levels 
are similar for wild type and the ERK8(Q300A) mutant, which 
does not bind PCNA (Figs. 3 D and 4 B). It is also unlikely that 
ERK8 is recruited to chromatin by PCNA because, in contrast 
to PCNA, soluble ERK8 does not redistribute to the insoluble 
fraction in response to UVC (Fig. S5 C). Furthermore, the 
ERK8(Q300A) mutant associates with chromatin but not with 
PCNA. Additionally, ERK8 and PCNA only partially colocalize 
as 42% ± 10.9 of the nuclei positive for Venus-ERK8 costain for 
PCNA, whereas in nuclei positive for PCNA, 22% ± 5.4 of the 
cells costain with ERK8. Thus, ERK8 must be able to interact 
with chromatin in a PCNA-independent manner.
To investigate the mechanism by which ERK8 associates 
with the chromatin, we analyzed deletion mutants. ERK8 (1–475) 
was active, associated with chromatin, and stimulated prolifer-
ation similar to that of the wild type (Fig. 6, A and B). However, 
further deletions of the C terminus generated inactive constructs 
that did not target to chromatin (Fig. 6 A). We identified a repeat-
ing PXXXP motif, which is highly conserved among mammals, 
located between residues 371 and 398 (Fig. S5 D). Unexpect-
edly, mutations within this motif (ERK8 (P390A/P398A)) sub-
stantially increased the level of activation, as indicated by pERK8, 
compared with the wild type (Fig. 6 C). However, the mutant also 
Figure 6.  ERK8 activity is regulated by auto-
inhibition. (A) Representative images of wild-
type and mutant ERK8
CHROMATIN. MCF-10A cells 
were transduced with Venus-ERK8 constructs. 
Transduced cells were treated with detergent 
and a high salt wash and fixed. Venus-ERK8 
constructs  were  detected  by  direct  fluores-
cence. The right panel shows immunoblots of 
lysates normalized for Venus expression. The 
black line indicates that intervening lanes were   
removed. WCE, whole cell extract. Bar, 50 µm.   
(B) Graph of the proliferation rate of transduced 
MCF-10A cells between day 2 and 4 after 
transduction. Mean is shown (n = 7, quadrupli-
cates), and error bars indicate SEM. (C) Rela-
tive activity of wild type and ERK8 (P390A, 
P398A)  as  detected  by  pERK8.  Transduced 
MCF-10A lysates were divided into insoluble (I) 
and soluble (S) fractions and normalized to the 
levels of active ERK1/2, and total expression 
of Venus-tagged constructs and pERK8 was de-
termined. Active ERK1/2 levels were detected   
by  dual  phosphorylation  of  its  T-E-Y  motif.   
(D) The percentage of the total nuclei that stained 
for chromatin-bound Venus-ERK8 constructs after   
a detergent and high salt wash extraction. The   
total number of nuclei was determined by stain-
ing with DRAQ5. Venus-ERK8 constructs were 
detected by direct fluorescence. Mean is shown 
(n = 2, ≥50 cells/condition), and error bars in-
dicate SEM. LV, lentivirus.583 ERK8 and genomic integrity • Groehler and Lannigan
stress. We would speculate that in breast cancer cells, there is a 
mechanism to prevent HDM2 from associating with PCNA in 
the absence of active ERK8. Our results also suggest that loss of 
ERK8 activity is important in the transformation process.
We have identified two important functional domains in 
ERK8, the PIP box and the PXXXP motif. The PIP box is located 
within the kinase domain, and the PXXXP motif is in the 
C-terminal extension. To identify the region within the kinase 
domain that contains the PIP box, we modeled the ERK8 kinase 
domain to that of ERK2 and found that the PIP box is adjacent 
to the conserved docking (CD) domain. The CD domain con-
tributes but is not solely responsible for the interactions of the 
MAPK superfamily with their docking partners (Tanoue et al., 
2000, 2001; Zhang et al., 2003). A corresponding PIP box was 
not found in other members of the ERK1/2 or p38MAPK fami-
lies but was present in JNK1/3 (Fig. S5 F). It is not known 
whether JNK1/3 can interact with PCNA. The CD domain in 
ERK8 is unusual in that it contains a Cys residue, whereas all 
other members of the MAPK superfamily have an acidic residue 
in this position. It is possible that the Cys residue regulates the 
ability of ERK8 to interact with PCNA. The PXXXP motif func-
tions to regulate the association of ERK8 with chromatin and 
thereby indirectly regulates association with PCNA as only 
ERK8
CHROMATIN interacts with PCNA. PCNA is known to interact 
with a plethora of proteins that contain PIP boxes and the mech-
anism by which these interactions are regulated is unknown.
It is intriguing that a rapidly evolving kinase would con-
trol genomic stability via PCNA, which is a highly conserved 
protein. Curiously, mammary epithelial cells are susceptible to 
surviving cells showed an at least threefold increase in fragmented 
nuclei with the more potent ERK8 shRNA (Fig. 7 C). As trans-
formed cells are often genetically unstable (Hoeijmakers, 2001), we 
investigated whether ERK8 was functional in human breast cancer 
lines. MCF-7 cells contained endogenous ERK8, whereas ERK8 
was not detected in T47-D cells (Fig. 8 A). As the levels of endoge-
nous active ERK8 were below the detection of the pERK8 anti-
body, we ectopically expressed ERK8 in the breast lines. ERK8 
was only active in MCF-10A cells (Fig. 8 B). To confirm this analy-
sis, we silenced ERK8 in MCF-7 cells and found that PCNA levels 
were not altered because of the loss of ERK8 (Fig. 8 C). These re-
sults further suggest that ERK8 is inactive in MCF-7 cells as only 
the active form of ERK8 regulates PCNA turnover. These observa-
tions are consistent with the literature in which PCNA degradation 
via the 26S proteasome pathway was not observed in transformed 
cells in the absence of extrinsic genotoxic stress (Izumi et al., 2001; 
Wang et al., 2006; Yu et al., 2009). Collectively, these data argue 
that ERK8 control of PCNA levels is physiologically relevant, as 
ERK8 activity is inhibited or lost in transformed cells.
Discussion
We conclude that ERK8 is as a key controller of genomic stabil-
ity in mammary epithelial cells via its ability to regulate the 
formation of complexes containing PCNA. In untransformed 
mammary cells, ERK8 prevents the destruction of PCNA that is 
mediated via HDM2 (Fig. 8 D). Remarkably, a twofold reduc-
tion in PCNA levels is sufficient to cause extensive DNA dam-
age and mitotic failure even in the absence of extrinsic genotoxic 
Figure 7.  ERK8 is critical for genomic integrity in mammary epithelial cells. (A) Analysis of endogenous ERK8 knockdown in HME cells (HMEC) transduced 
with control or ERK8 shRNA for 5 d. The detergent-insoluble fraction (I) of the transduced lysates was normalized for Ran expression. (B) Analysis of DNA 
damage by comet assay of transduced HME cells treated without irradiation or 2 h after UVC treatment. The left panel shows lysates from transduced HME 
cells that were normalized for Ran expression and immunoblotted. (C) Analysis of DNA morphology by Hoechst staining of transduced MCF-10A cells kept 
in long-term culture (2 wk). Arrows indicate micronuclei. The percentage of the total cell population that contained micronuclei was determined. Mean is 
shown (≥500 cells), and error bars indicate SEM. Luc, luciferase; LV, lentivirus. Bars: (B) 50 µm; (C) 10 µm.JCB • VOLUME 190 • NUMBER 4 • 2010   584
The short hairpin sequence including the ERK8-targeting shRNAs 
(in bold) are (ERK8-1) 5-GATCCCCACATTTACCTGGTGTTTGATTCAAGAGA-
TCAAACACCAGGTAAATGTTTTTTGGAAA-3  and  (ERK8-2)  5-GATCC-
CCGACAGATGCCCAGAGAACATTCAAGAGATGTTCTCTGGGCATCTGTCTT-
TTTGGAAA-3. The short hairpin sequence including the luciferase-targeting 
shRNAs (in bold) is 5-GATCCCCCGTACGCGGAATACTTCGATTCAAGAGA-
TCGAAGTATTCCGCGTACGTTTTTGGAA-3 (Malliri et al., 2004). GST-PIP 
and GST-PIPm were generated by subcloning into pGEX2T (GE Healthcare) 
the annealed oligonucleotides with the upper strand sequences 5-GATCCC-
AGGCACTGCAGCACCCCTACGTGCAGAGGTTCCACTGCCCCTGAG-3 
and 5-GATCCCAGGCACTGGCGCACCCCTACGTGCAGAGGTTCCACT-
GCCCCTGAG-3. All shRNA, deletion, and mutant constructs were verified 
by sequencing (Biomolecular Research Core, University of Virginia).
Cell culture and treatment
MCF-10A, MCF-7, and T47D were cultured as indicated by the American 
Type  Culture  Collection.  Primary  HME  cells  were  purified  from  tissue   
(McCaffrey and Macara, 2009) and cultured (Eisinger-Mathason et al., 2008). 
For irradiation, the cells were washed with PBS and exposed to 20 J/m
2 UVC. 
Comet  assay  was  performed  according  to  the  manufacturer  (Trevigen, 
Inc.)  and  electrophoresed  under  alkaline  conditions  (275  mA  for   
30 min at 4°C). Cell fractionation was performed as described previously 
transformation by loss of BRCA1, which is also important in 
DNA metabolism (Saal et al., 2008). We speculate that because 
mammary epithelial cells are subjected to proliferative signals 
throughout the reproductive life of the animal that additional lay-
ers of regulation are required to ensure their genomic integrity.
Materials and methods
Plasmids and lentiviral production
Constructs used to generate lentivirus, including pSPAX2, pLVTHM, and 
pMD2G, were provided by D. Trono (Swiss Federal Institute of Technol-
ogy,  Lausanne,  Switzerland;  Zufferey  et  al.,  1997).  pLV-Venus  and   
pLV-mRFP lentivirus constructs were provided by I.G. Macara (Univer-
sity of Virginia, Charlottesville, VA; McCaffrey and Macara, 2009).   
pCMV5HIS6-Ub was provided by D. Wotton (University of Virginia). 
pWPI was purchased from Addgene. Lentiviral production was performed 
as described previously (McCaffrey and Macara, 2009) but titered using 
MCF-10A cells.
Figure 8.  Breast cancer cells do not have active ERK8. (A) Analysis of endogenous ERK8 levels in breast cancer cell lines. Whole cell extracts (WCE) 
from different breast cell lines were normalized for Ran. For comparison, MCF-10A cells were transduced with luciferase (Luc) or ERK8 shRNA, and the 
insoluble (I) fraction was analyzed 5 d after transduction. (B) Lysates from the various breast lines were transduced with Venus-ERK8, normalized to expres-
sion of Venus-ERK8, and immunoblotted for active ERK8 (pERK8). (A and B) The black lines indicate that intervening lanes were removed. (C) Loss of ERK8 
does not decrease PCNA levels in MCF-7 cells. MCF-7 cells were transduced with luciferase or ERK8 shRNA for 5 d. Lysates were normalized to Ran and   
immunoblotted. (D) Model of ERK8 regulation of PCNA levels. Active ERK8 preferentially binds to the chromatin through its binding partners. ERK8
CHROMATIN 
and PCNA
CHROMATIN interact via the ERK8 PIP box. Loss of ERK8 binding to PCNA via silencing or mutation of the PIP domain results in the increased   
recruitment of HDM2, which enhances PCNA turnover. Autoinhibition is alleviated by mutating Pro390 and Pro398. However, these mutations interfere 
with chromatin binding. LV, lentivirus.585 ERK8 and genomic integrity • Groehler and Lannigan
(900 rpm). The immunoprecipitates were washed five times in the appropri-
ate immunoprecipitation buffer, three times high salt buffer (10 mM Hepes,   
pH 7.4, 300 mM NaCl, 10 mM KCl, and 1 mM EDTA), and three times 
with the immunoprecipitation buffer. The beads were boiled in 2× SDS lysis 
buffer (0.12 M Tris-Cl, pH 6.8, 4% SDS, 20% glycerol, 0.2 M DTT, and 
0.008% bromophenol blue), heated to 100°C for 5 min
Pulse-chase labeling
Cells were washed and preincubated for 4 h with cold labeling media 
(Met-free DMEM/F12 [Sigma-Aldrich], 5% dialyzed horse serum, 0.5 µg/ml 
hydrocortisone, 100 ng/ml cholera toxin, 10 µg/ml insulin, and 5.75 µM 
cold Met). l-[
35S]Met (200 µCi/ml; 800 Ci/mmol; PerkinElmer) was added 
and incubated for 4 h. After washing with labeling media plus 2 mM cold 
Met, the cells were replaced in their normal growth media and harvested 
for immunoprecipitation.
Statistical analysis
Data are presented as mean ± SEM; Student’s two-tailed t test was used for 
comparisons, with P < 0.05 considered significant.
Online supplemental material
Fig.  S1  shows  that  ERK8  regulates  the  cell  cycle.  Fig.  S2  shows  that 
loss  of  ERK8  increases  DNA  damage.  Fig.  S3  shows  that  ERK8  regu-
lates PCNA turnover. Fig. S4 shows that inhibition of p53 degradation 
does not alter PCNA protein levels. Fig. S5 examines the activation,   
levels, and subcellular distribution of ERK8 in response to DNA-damaging   
agents. Online supplemental material is available at http://www.jcb 
.org/cgi/content/full/jcb.201002124/DC1.
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(Avkin  et  al.,  2006).  Transient  transfection  was  performed  with  Lipo-
fectamine 2000 (Invitrogen) reagent using nontargeting siRNA #1, human 
MDM2 SMARTpool siRNA, or human PCNA SMARTpool siRNA (Thermo 
Fisher Scientific). The following chemicals were used: nutlin-3 (EMD);   
hydroxyurea, etoposide, cisplatin, and MMS (methyl methane sulphonate; 
Sigma-Aldrich); and H2O2 (Thermo Fisher Scientific) and MNNG (N-methyl-
N’-N-nitrosoguanidine; TCI America).
Immunodetection and immunofluorescence
Primary antibodies used were monoclonal anti-p27, rabbit anti–RFC-1, 
monoclonal anti-GST, rabbit anti-HA, monoclonal anti-HDM2, monoclonal 
anti-p53, and monoclonal anti-PCNA (Santa Cruz Biotechnology, Inc.); 
monoclonal anti–cyclin D1, monoclonal anti-Rb, rabbit anti–phospho-Ser428 
ATR, rabbit anti–phospho-Thr68 Chk2, and rabbit anti-Chk2 (Cell Signal-
ing Technology); monoclonal anti–phospho-Tyr, rabbit anti–phospho-Ser, 
rabbit anti–cyclin E, and monoclonal anti–-H2AX (Millipore); rabbit anti–
phospho-Thr (Invitrogen); monoclonal anti-Rad9 and rabbit anti–phospho-
MAPK  (pThr202/pTyr204;  Thermo  Fisher  Scientific);  rabbit  anti-ERK8   
(Abgent); monoclonal anti-PCNA (Dako); monoclonal anti-Ran (BD); mono-
clonal anti–cyclin A (Novocastra); goat anti-GFP and rabbit anti-GFP   
(Venus; Abcam); and monoclonal anti-HA (12CA5; Lymphocyte Culture 
Center, University of Virginia). Secondary antibodies used were goat anti–
mouse, goat anti–rabbit, and donkey anti–goat (Jackson ImmunoResearch 
Laboratories, Inc.).
Detection of PCNA and Venus-tagged chromatin-binding proteins 
was adapted from Sporbert et al. (2002). In brief, cells were plated on 
coverslips, washed twice with ice-cold PBS, and permeabilized for 30 s 
with ice-cold cytoskeleton buffer (10 mM Pipes, pH 6.8, 250 mM sucrose, 
50 mM NaCl, 2 mM MgCl2, 2 mM EGTA, and 0.1% Triton X-100). The 
permeabilized  cells  were  washed  with  ice-cold  wash  buffer  (4.3  mM 
Na2HPO4, 1.5 mM KH2PO4, 520 mM NaCl, and 2.66 mM KCl) and fixed 
in ice-cold methanol at 20°C for 5 min. PCNA was detected by indirect 
fluorescence with a mouse monoclonal anti-PCNA antibody (clone PC-10; 
Dako) and an anti–mouse IgG antibody conjugated with Alexa Fluor 546 
(Invitrogen). Direct fluorescence was observed with Venus fusion proteins.
Detection of -H2AX was adapted from Jørgensen et al. (2007). 
Cells were plated on coverslips, washed twice in ice-cold PBS, followed by ex-
traction for 10 min on ice with Triton buffer (20 mM Hepes, pH 7.4, 300 mM 
sucrose, 50 mM NaCl, 3 mM MgCl2, and 0.5% Triton X-100), and fixed 
with 4% paraformaldehyde for 10 min. -H2AX was detected by indirect 
fluorescence with phospho-Ser139 histone H2A.X (clone JBW301; Milli-
pore) primary antibody and an anti–mouse IgG antibody conjugated   
with Alexa Fluor 546. DNA was stained with Hoechst (Sigma-Aldrich) or 
DRAQ5 (Axxora).
Densitometry  analysis  for  immunodetection  was  performed  using   
ImageJ (National Institutes of Health) or ImageQuant (GE Healthcare) soft-
ware.  Indirect  and  direct  fluorescent  images  were  obtained  at  room 
temperature  with  a  laser-scanning  microscope  (510/Meta/FCS;  Carl 
Zeiss, Inc.) using a 40× NA 1.3 oil immersion lens. Images were acquired 
using LSM-FCS software (Carl Zeiss, Inc.) and quantitated using Openlab   
3.1.4 (PerkinElmer) and ImageJ software. Images were processed in Photo-
shop version CS3 (Adobe).
Proliferation and cell cycle assays
Cells were analyzed for proliferation using a Luminescent Cell Viability   
Assay (Promega). Fixed cells (2% paraformaldehyde, pH 7.4, and 0.05% 
Triton X-100) were incubated with 40 µM DRAQ5, washed, and analyzed 
on a FACSCalibur (BD) using FlowJo 6.4.2 software (Tree Star, Inc.; Flow 
Cytometry Core Facility, University of Virginia).
Immunoprecipitation
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